High Altitude Polycythemia
Conditions
Brief summary
A multicenter, randomized controlled trial was designed to evaluate the effectiveness and safety of the comprehensive traditional Tibetan medicine program combined with remote ischemic conditioning on high altitude polycythemia.
Interventions
DEVICERemote Ischemic Conditioning
Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.
DRUGTibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)
Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
Sponsors
Capital Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with high-altitude polycythemia aging 18 to 65 years.
Exclusion criteria
* Allergic to Tibetan medicine ingredients; * Inappropriate to receive Tibetan medicine treatment and/or remote ischemic conditioning.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of effective treatment | Baseline and 1 month after treatment. | The hemoglobin levels decreased ≥20% after treatment compared to pre-treatment. |
Contacts
Primary ContactYuan Wang, M.D.
Outcome results
None listed